Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin

Ce dossier présente une série d'articles concernant le métabolisme des cellules cancéreuses, notamment les processus métaboliques susceptibles de constituer des cibles thérapeutiques

Résumé en anglais

Epidemiological studies suggest that metformin may reduce the incidence of cancer in patients with diabetes and multiple late phase clinical trials assessing the potential of repurposing this drug are underway. Transcriptomic profiling of tumour samples is an excellent tool to understand drug bioactivity, identify candidate biomarkers and assess for mechanisms of resistance to therapy.